Therapeutic Monoclonal Antibodies Against Cancer Testicular Antigen

COOPERATION OPTIONS


license

FROM 120 million RUR

Research partnership

from 45 MILLION RUR

more detail

about the project

Therapeutic Monoclonal Antibodies Against Cancer Testicular Antigen, API 

AN UNIQUE PRODUCT WITH REDUCED TOXICITY FOR THE TREATMENT OF SEVERAL TYPES OF CANCER.

A group of genes encoding cancer-testicular antigens (CTAs) is activated in the cells of most malignant tumors. CTAs are considered as a promising target for immunotherapy of malignant tumors. Recombinant therapeutic antibodies to CTAs NY-ESO-1 are being developed, which will expand the treatment arsenal for neoplasms of different histological origin. 

The oncotherapy success depends on the degree of toxicity of the treatment drugs. Currently, one treatment option is the use of immunotherapy with the formation of cellular immunity using vaccines based on cancer testicular antigens (CTAs) and anti-CTA monoclonal antibodies. Another treatment option is the direct use of anti-CTA monoclonal antibodies for tumor therapy. 

CTAs are a family of tumor-associated proteins that are normally expressed in normal male germ cells and in various cancers, but not in somatic cells. Anti-CTA monoclonal antibodies offers a significant reduction in toxicity while targeting cancer cells. 

Stage of development

THERAPEUTIC MONOCLONAL ANTIBODIES AGAINST CANCER TESTICULAR ANTIGEN

COOPERATION OPTIONS


LICENSE

FROM 120 MILLION RUR

RESEARCH PARTNERSHIP

FROM 45 MILLION RUR

more detail

ABOUT THE PROJECT

THERAPEUTIC MONOCLONAL ANTIBODIES AGAINST CANCER TESTICULAR ANTIGEN, API

AN UNIQUE PRODUCT WITH REDUCED TOXICITY FOR THE TREATMENT OF SEVERAL TYPES OF CANCER.

A group of genes encoding cancer-testicular antigens (CTAs) is activated in the cells of most malignant tumors. CTAs are considered as a promising target for immunotherapy of malignant tumors. Recombinant therapeutic antibodies to CTAs NY-ESO-1 are being developed, which will expand the treatment arsenal for neoplasms of different histological origin.

The oncotherapy success depends on the degree of toxicity of the treatment drugs. Currently, one treatment option is the use of immunotherapy with the formation of cellular immunity using vaccines based on cancer testicular antigens (CTAs) and anti-CTA monoclonal antibodies. Another treatment option is the direct use of anti-CTA monoclonal antibodies for tumor therapy.

CTAs are a family of tumor-associated proteins that are normally expressed in normal male germ cells and in various cancers, but not in somatic cells. Anti-CTA monoclonal antibodies offers a significant reduction in toxicity while targeting cancer cells.

Stage of development

STAGE OF DEVELOPMENT 

& RESULTS OF INTELLECTUAL ACTIVITY STATUS


application

Сan be used in combination therapy with drugs from the PD-1/PD-L1 blocker group and as an API for the drug creation for the treatment of various types of oncology, primarily for melanoma, lung cancer and colorectal cancer treatment.

Description:  lyophilizate for the preparation of a solution for parenteral injection.

effect 

The principle of TER MAT action is based on their interaction with the cancer-testicular antigen NY-ESO-1 and the activation of anti-tumor immunity mechanisms.

BENEFITS

The product has no analogues in the world
Reduced side effects in comparison with chemotherapy drugs
Melanoma and lung cancer combined therapy with PD-1/PD-L1 blockers is possible, It reduces the recurrence rate and improves survival ratio
Recognizes and destroys tumor cells carrying the cancer testicular antigen in the therapy of tumors of different histological origin
The product cost price is lower than that of foreign drugs as well as Russian biosimilar drugs

COOPERATION OPTIONS

Options for project implementation include Intellectual Property license agreement and/or further product development together with investor.
license agreement 

Conclusion of agreements on disposal of exclusive intellectual property rights (license agreements). 

Approximate investment amount: 

• Granting the right to use results of intellectual activity - from RUB 120 million RUR

• Royalty 5%

Small Innovation Enterprise (SIE)

Creation of the project company as a Small Innovation Enterprise (SIE), the founders of which include IBCh RAS and some investor & scientists-developers.

The aim: to bring research to the market launching stage and to organize product manufacturing and sales.

Approximate investment amount: 

Starting at 475 million RUR 

Small Innovation Enterprise (SIE)

Creation of the project company as a Small Innovation Enterprise (SIE), the founders of which include IBCh RAS and some investor & scientists-developers.

The aim: to reach the further research stage(s) and to sale of the scientific product in the form of sublicensing.

Approximate investment amount:

• Preclinical studies
Starting at 45 million RUR

• Clinical trials, phase 1
Starting at 60 million RUR

• Clinical trials, phase 2
Starting at 100 million RUR

• Clinical trials, phase 3
Starting at 200 million RUR

investment partnership agreements

Conclusion of investment partnership agreements for further research stages on the investor basis with the participation of IBCh RAS.

The aim: to obtain a scientific product or "ready to market" product.

Approximate investment amount: 

• Preclinical studies
Starting at 45 million RUR

• Clinical trials, phase 1
Starting at 60 million RUR

• Clinical trials, phase 2
Starting at 100 million RUR

• Clinical trials, phase 3
Starting at 200 million RUR

• Start manufacturing
Starting at 20 million RUR

• Promotion activities
Starting at 50 million RUR

DEVELOPERS

The Shemyakin & Ovchinnikov Institute of bioorganic chemistry (IBCh) of the Russian Academy of Sciences is one of the largest Russian scientific organizations. The Institute is a leader in fundamental and innovative researches on the fields of molecular, structural and cell biology, bioorganic chemistry, biophysics, bioengineering, cell technologies, “in vivo” molecular based bioimaging, genome editing, bioinformatics etc. This multidisciplinary structure allows large-scale research at the interface of sciences, where the most interesting scientific discoveries are born today.

The hallmark of the IBCh RAS is the concentration of efforts and resources on solving the most urgent and complicated problems on the field of life sciences. Talented young people and leading specialists, including Russian and foreign science leaders, Nobel Prize laureates and members of the international advisory council of the Institute are involved in.

Project Team:
• Dmitriy Dolgikh, Ph.D. in Biology, Head of the Laboratory of Recombinant Immunoglobulins of IBCh RAS
• Teymur Aliev, Researcher, Laboratory of Recombinant Immunoglobulin Engineering of IBCh RAS
• Andrey Misyurin, Ph.D. in Biology, General Director of “GenoTechnology”, Bioorganica Consortium member 


авторы разработки

доктор

биологических наук

Долгих

Дмитрий Александрович

Заведующий лабораторией инженерии рекомбинатных иммуноглобулинов ЦНТИ ИБХ РАН
Кандидат биологических

наук

Мисюрин

Андрей Витальевич

Генеральный директор ООО "ГеноТехнология"
кандидат химических наук


Алиев

Теймур Кантамирович

Лаборатория инженерии рекомбинантных иммуноглобулинов ЦНТИ ИБХ РАН

CONTACT us

get in touch

On cooperation issues please contact the head of NTI Center project department
Sergey Semenov
E-mail consortium@cnti-ibch.ru
address 16/10, Miklukho-Maklaya St, Moscow, Russian Federation, 117997
All products and services of NTI Center IBHh RAS
view more